Source 1review2021Acta Biochimica Polonica
Toolkit/gene circuits
gene circuits
Also known as: gene-circuit therapy
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Gene circuits are higher-order engineered synthetic biomolecular systems discussed as components of therapeutic gene-circuit therapy. The cited 2021 review describes proof-of-principle and clinical applications of gene circuits in engineered therapeutics, but does not provide a specific circuit architecture in the supplied evidence.
Usefulness & Problems
Why this is useful
Gene circuits are presented as synthetic biology tools for therapeutic contexts, particularly where engineered therapeutics require more sophisticated control than conventional gene and cell therapy approaches. Their relevance is framed by the stated limitation that current approaches lack precise control over the timing, contextuality, and level of transgene expression.
Source:
Synthetic biology offers new opportunities for quantitative functionality in designing therapeutic systems and their components.
Problem solved
The supplied evidence indicates that gene circuits are intended to address insufficient precision in transgene regulation in existing gene and cell therapies. Specifically, they are positioned against deficits in temporal control, context dependence, and expression-level control.
Source:
Synthetic biology offers new opportunities for quantitative functionality in designing therapeutic systems and their components.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Mechanisms
No mechanism tags yet.
Techniques
Computational DesignTarget processes
No target processes tagged yet.
Implementation Constraints
The provided evidence does not describe construct design, delivery modality, expression system, cofactors, or therapeutic payload configuration for any specific gene circuit. Only the general therapeutic context and future development toward advanced gene-circuit therapy are stated.
The supplied evidence is from a review-level scope statement and does not specify particular gene-circuit designs, molecular components, host systems, or benchmarked outcomes. As a result, mechanism, implementation, and performance claims cannot be made beyond their therapeutic framing and intended control functions.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Current gene and cell therapy approaches are described as lacking precise control over timing, contextuality, and levels of transgene expression.
Current approaches of gene and cell therapy fail to deliver such command and rely on semi-quantitative methods with limited influence on timing, contextuality and levels of transgene expression, and hence on therapeutic function.
Current gene and cell therapy approaches are described as lacking precise control over timing, contextuality, and levels of transgene expression.
Current approaches of gene and cell therapy fail to deliver such command and rely on semi-quantitative methods with limited influence on timing, contextuality and levels of transgene expression, and hence on therapeutic function.
Current gene and cell therapy approaches are described as lacking precise control over timing, contextuality, and levels of transgene expression.
Current approaches of gene and cell therapy fail to deliver such command and rely on semi-quantitative methods with limited influence on timing, contextuality and levels of transgene expression, and hence on therapeutic function.
Current gene and cell therapy approaches are described as lacking precise control over timing, contextuality, and levels of transgene expression.
Current approaches of gene and cell therapy fail to deliver such command and rely on semi-quantitative methods with limited influence on timing, contextuality and levels of transgene expression, and hence on therapeutic function.
Current gene and cell therapy approaches are described as lacking precise control over timing, contextuality, and levels of transgene expression.
Current approaches of gene and cell therapy fail to deliver such command and rely on semi-quantitative methods with limited influence on timing, contextuality and levels of transgene expression, and hence on therapeutic function.
Current gene and cell therapy approaches are described as lacking precise control over timing, contextuality, and levels of transgene expression.
Current approaches of gene and cell therapy fail to deliver such command and rely on semi-quantitative methods with limited influence on timing, contextuality and levels of transgene expression, and hence on therapeutic function.
Current gene and cell therapy approaches are described as lacking precise control over timing, contextuality, and levels of transgene expression.
Current approaches of gene and cell therapy fail to deliver such command and rely on semi-quantitative methods with limited influence on timing, contextuality and levels of transgene expression, and hence on therapeutic function.
The review covers proof-of-principle and clinical applications of engineered synthetic biomolecules and gene circuits in therapeutic contexts.
Here, we discuss synthetic biology tools in their therapeutic context, with examples of proof-of-principle and clinical applications of engineered synthetic biomolecules and higher-order functional systems, i.e. gene circuits.
The review covers proof-of-principle and clinical applications of engineered synthetic biomolecules and gene circuits in therapeutic contexts.
Here, we discuss synthetic biology tools in their therapeutic context, with examples of proof-of-principle and clinical applications of engineered synthetic biomolecules and higher-order functional systems, i.e. gene circuits.
The review covers proof-of-principle and clinical applications of engineered synthetic biomolecules and gene circuits in therapeutic contexts.
Here, we discuss synthetic biology tools in their therapeutic context, with examples of proof-of-principle and clinical applications of engineered synthetic biomolecules and higher-order functional systems, i.e. gene circuits.
The review covers proof-of-principle and clinical applications of engineered synthetic biomolecules and gene circuits in therapeutic contexts.
Here, we discuss synthetic biology tools in their therapeutic context, with examples of proof-of-principle and clinical applications of engineered synthetic biomolecules and higher-order functional systems, i.e. gene circuits.
The review covers proof-of-principle and clinical applications of engineered synthetic biomolecules and gene circuits in therapeutic contexts.
Here, we discuss synthetic biology tools in their therapeutic context, with examples of proof-of-principle and clinical applications of engineered synthetic biomolecules and higher-order functional systems, i.e. gene circuits.
The review covers proof-of-principle and clinical applications of engineered synthetic biomolecules and gene circuits in therapeutic contexts.
Here, we discuss synthetic biology tools in their therapeutic context, with examples of proof-of-principle and clinical applications of engineered synthetic biomolecules and higher-order functional systems, i.e. gene circuits.
The review covers proof-of-principle and clinical applications of engineered synthetic biomolecules and gene circuits in therapeutic contexts.
Here, we discuss synthetic biology tools in their therapeutic context, with examples of proof-of-principle and clinical applications of engineered synthetic biomolecules and higher-order functional systems, i.e. gene circuits.
Synthetic biology is presented as offering opportunities for quantitative functionality in the design of therapeutic systems and their components.
Synthetic biology offers new opportunities for quantitative functionality in designing therapeutic systems and their components.
Synthetic biology is presented as offering opportunities for quantitative functionality in the design of therapeutic systems and their components.
Synthetic biology offers new opportunities for quantitative functionality in designing therapeutic systems and their components.
Synthetic biology is presented as offering opportunities for quantitative functionality in the design of therapeutic systems and their components.
Synthetic biology offers new opportunities for quantitative functionality in designing therapeutic systems and their components.
Synthetic biology is presented as offering opportunities for quantitative functionality in the design of therapeutic systems and their components.
Synthetic biology offers new opportunities for quantitative functionality in designing therapeutic systems and their components.
Synthetic biology is presented as offering opportunities for quantitative functionality in the design of therapeutic systems and their components.
Synthetic biology offers new opportunities for quantitative functionality in designing therapeutic systems and their components.
Synthetic biology is presented as offering opportunities for quantitative functionality in the design of therapeutic systems and their components.
Synthetic biology offers new opportunities for quantitative functionality in designing therapeutic systems and their components.
Synthetic biology is presented as offering opportunities for quantitative functionality in the design of therapeutic systems and their components.
Synthetic biology offers new opportunities for quantitative functionality in designing therapeutic systems and their components.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug gene-circuits
Here, we discuss synthetic biology tools in their therapeutic context, with examples of proof-of-principle and clinical applications of engineered synthetic biomolecules and higher-order functional systems, i.e. gene circuits. We also present the prospects of future development towards advanced gene-circuit therapy.
Source:
limitation of current approachessupports
Current gene and cell therapy approaches are described as lacking precise control over timing, contextuality, and levels of transgene expression.
Current approaches of gene and cell therapy fail to deliver such command and rely on semi-quantitative methods with limited influence on timing, contextuality and levels of transgene expression, and hence on therapeutic function.
Source:
review scope statementneutral
The review covers proof-of-principle and clinical applications of engineered synthetic biomolecules and gene circuits in therapeutic contexts.
Here, we discuss synthetic biology tools in their therapeutic context, with examples of proof-of-principle and clinical applications of engineered synthetic biomolecules and higher-order functional systems, i.e. gene circuits.
Source:
therapeutic potentialsupports
Synthetic biology is presented as offering opportunities for quantitative functionality in the design of therapeutic systems and their components.
Synthetic biology offers new opportunities for quantitative functionality in designing therapeutic systems and their components.
Source:
Comparisons
Source-backed strengths
The cited review states that gene circuits have been considered in both proof-of-principle and clinical application settings for engineered therapeutics. This supports their conceptual and translational relevance, although no quantitative performance metrics are provided in the supplied evidence.
Ranked Citations
- 1.